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Abstract
Background
Each inherited retinal disorder is rare, but together, they affect millions of people worldwide.
No treatment is currently available for these blinding diseases, but promising new options—
including gene therapy—are emerging. Arguably, the most prevalent retinal dystrophy is
Stargardt disease. In each case, the specific combination of ABCA4 variants (> 900 identi-
fied to date) and modifying factors is virtually unique. It accounts for the vast phenotypic
heterogeneity including variable rates of functional and structural progression, thereby
potentially limiting the ability of phase I/II clinical trials to assess efficacy of novel therapies
with few patients. To accommodate this problem, we developed and validated a sensitive
and reliable composite clinical trial endpoint for disease progression based on structural
measurements of retinal degeneration.
Methods and findings
We used longitudinal data from early-onset Stargardt patients from the Netherlands (devel-
opment cohort, n = 14) and the United Kingdom (external validation cohort, n = 18). The
composite endpoint was derived from best-corrected visual acuity, fundus autofluores-
cence, and spectral-domain optical coherence tomography. Weighting optimization tech-
niques excluded visual acuity from the composite endpoint. After optimization, the endpoint
outperformed each univariable outcome, and showed an average progression of 0.41˚ reti-
nal eccentricity per year (95% confidence interval, 0.30–0.52). Comparing with actual longi-
tudinal values, the model accurately predicted progression (R2, 0.904). These properties
were largely preserved in the validation cohort (0.43˚/year [0.33–0.53]; prediction: R2,
0.872). We subsequently ran a two-year trial simulation with the composite endpoint, which
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detected a 25% decrease in disease progression with 80% statistical power using only 14
patients.
Conclusions
These results suggest that a multimodal endpoint, reflecting structural macular changes,
provides a sensitive measurement of disease progression in Stargardt disease. It can be
very useful in the evaluation of novel therapeutic modalities in rare disorders.
Introduction
Inherited blindness affects millions of people worldwide—the majority suffering from retinal
disease [1]. Inherited retinal disorders now represent the primary cause of blindness in the
working age population in the UK, and secondary in childhood [2]. They are clinically and
genetically heterogeneous, caused by sequence variants in more than 300 distinct genes
(RetNet) http://www.sph.uth.tmc.edu)/. Mutations in the ATP-binding cassette, subfamily A,
member 4 (ABCA4) gene are linked to arguably the most common retinal dystrophy: autoso-
mal recessive Stargardt disease (STGD1) [3]. Each case of STGD1 is, in a sense, unique by
specific combinations of pathogenic ABCA4 variants (> 900 variants identified to date) and
modifying factors. Consequently, the natural course is highly variable, ranging from severe
early-onset rapid degeneration [4, 5] to relatively mild late-onset disease [6, 7]. The eventual
vision loss results from progressive impairment and degeneration of photoreceptors and their
supporting retinal pigment epithelium (RPE) [8].
Recently, significant advancement has been made in the development of therapies that aim
to slow disease progression, or even to restore lost photoreceptors in STGD1. These include
replacement of ABCA4 by gene therapy [9], cell-based therapies [10], and pharmacological
strategies including slowing the visual cycle or inhibition of vitamin A dimerization [11, 12].
Clinical trials are currently recruiting patients to assess safety and efficacy. However, successful
evaluation of these therapies critically hinges on sensitive and reliable measures for disease
progression.
To monitor efficacy of a treatment, current trials generally use functional endpoints (S1
Table). One of the most widely used U.S. Food and Drug Administration-approved endpoints
is best-corrected visual acuity (BCVA) [13]. However, the main disadvantage of BCVA lies in
its extremely variable deterioration rate in patients with retinal dystrophies. Moreover, visual
acuity decline can be a late phenomenon following a long period of pathophysiological changes
[14]. As a result, the endpoint has an unfavorable signal-to-noise ratio, which leads to a need
for longer follow-up and large cohorts. This setup is impossible to achieve given the unaccept-
able long time frame and the rarity of these disorders.
However, studies suggest that structural abnormalities gradually expand centrifugally [5,
15], starting from the foveal center towards the periphery. Although loss of foveal function is
highly important from a patient’s perspective, it is only one step in the overall pattern of retinal
degeneration. This pattern is thought to initiate with melanization abnormalities in the RPE
[16, 17], and is trailed by changes in lipofuscin fluorophores [18–20], degeneration of the RPE
[21–23], and loss of the ellipsoid zone (EZ) and external limiting membrane (ELM) [24–27].
However, these transition zones are not present in every case, and do not always start at the
center of the macula; many are still not well understood.
A composite outcome measure is likely to outperform single candidate outcome measures
[28] in accurately measuring short-term progression, and can therefore increase statistical
A multimodal model of progression in Stargardt disease
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power of pivotal clinical trials. In this study, we chose to measure four structural metrics of
expanding transition zones and one psychophysical metric over time in a cohort of patients
with early-onset STGD1. These included questionably and definitely decreased autofluores-
cence (QDAF and DDAF), and loss of the EZ, ELM and BCVA. Next, we assessed intra- and
inter-grader differences. Having standardized all metrics, we then calculated an optimal
weighted composite. The same measurements were made in a second patient cohort, and,
using the composite, we predicted and compared progression with real longitudinal values.
We subsequently ran a simulation to examine the power of the composite endpoint and alter-
natives to detect a difference in outcome given a theoretical intervention with a significant
impact on progression rate.
Results
Characteristics of the initial patient population
A cohort of 14 patients with early-onset STGD1 ascertained at the Radboud university medical
center in Nijmegen had a median age at disease onset of 9 years (range, 4–11). Seventy-four
eye-visits of 28 eyes were included in this study (range, 2–4 visits per eye). At the time of inclu-
sion, all eyes had abnormal fundus autofluorescence (FAF) imaging and evidence of loss of
photoreceptors on spectral-domain optical coherence tomography (SD-OCT), primarily lim-
ited to the macula at their baseline visit. Due to their early disease onset and rapidly progres-
sive macular changes, a significant proportion of patients were expected to progress to retina-
wide disease over time [4, 5, 29]. The follow-up time ranged from 1.1 to 9.7 years (median,
4.7).
Visual acuity measurements indicate extra-macular dysfunction
At the first visit, the Nijmegen cohort had a median BCVA of 20/205 Snellen in both eyes. The
highest BCVA can be obtained at the fovea and diminishes rapidly by retinal eccentricity (ε) as
shown in Fig 1 [30]. According to Fig 1, 20/205 Snellen corresponds to 12.76˚ of ε by BCVA
(εBCVA), the equivalent diameter being 7.7 mm. Assuming a 5.5 mm diameter of the macula,
the high degree of eccentricity indicated that the patients’ visual function corresponded to
extra-macular disease at baseline.
Structural parameters are measured with high reproducibility
To assess the accuracy and reliability of measurements on FAF imaging and SD-OCT, we ana-
lyzed inter- and intra-grader agreements. These included transition zones of QDAF and
DDAF areas, and transverse loss of the EZ and ELM. The absolute mean (± standard devia-
tion) differences within one grader for εQDAF, εDDAF, εEZ and εELM were 0.19 ± 0.18˚, 0.20 ±
0.23˚, 0.10 ± 0.12˚, and 0.20 ± 0.22˚, respectively. The intra-grader measurements were highly
correlated with intraclass correlation coefficients (95% confidence interval) of 0.995 (0.989–
0.997), 0.994 (0.986–0.997), 0.998 (0.993–0.999), and 0.998 (0.994–0.999), respectively. The
absolute mean differences between graders were 0.26 ± 0.23˚, 0.22 ± 0.21˚, 0.26 ± 0.23˚, and
0.23 ± 0.18˚, respectively. The measurements from both graders were highly correlated with
intraclass correlation coefficients of 0.992 (0.986–0.995), 0.994 (0.990–0.996), 0.992 (0.971–
0.998), and 0.997 (0.992–0.999), respectively.
Initial transition zones on retinal imaging
We measured the abnormalities of lipofuscin fluorophores in the RPE by determining both
the transition zones of DDAF and QDAF on FAF imaging as shown in Fig 2A [20, 31]. At the
A multimodal model of progression in Stargardt disease
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first visit, the median εDDAF and εQDAF for both eyes were 1.80˚ (range, 0–5.60) and 4.22˚
(range, 1.68–7.67), equivalent to an area of 0.92 mm2 and 5.03 mm2, respectively. Additionally,
we measured the horizontal loss of the photoreceptor-related ELM and EZ through the foveal
center on SD-OCT (Fig 2B). At the first visit, the median εELM and εEZ for both eyes were
5.09˚ (range, 2.50–10.71) and 3.54˚ (range, 2.99–7.83), equivalent to a loss of 3.05 mm and
2.12 mm, respectively.
A structural composite measure of expanding transition zones
outperforms univariable measures
We assessed the change of each individual parameter over time by linear mixed-effects models.
The models accounted for between-patients and between-eyes effects. We then calculated the
sensitivity of each parameter by the ratio of the population mean slope, i.e., overall disease pro-
gression, and the residual standard deviation (mean-to-standard-deviation ratio, MSDR). εQDAF
had the highest sensitivity (MSDR, 2.32), whereas εBCVA had the lowest (MSDR, 0.08). The
MSDR for εEZ could not be obtained as there were not sufficient measurements available. Sensi-
tivities of all individual parameters are shown in Table 1. We constructed a composite variable
from changes in ε as measured by BCVA, QDAF, DDAF, EZ, and ELM. Results from MSDR
calculations of every potential weighting combination indicated that the most sensitive compos-
ite consisted of a weighted mean of changes in εBCVA (0%), εQDAF (25%), εDDAF (5%), εEZ (55%),
and εELM (15%). We observed an overall progression rate of 0.41˚/year (95% confidence inter-
val, 0.30–0.52). Potential MSDRs for all measures with different weighting scores are shown in
Fig 3. Based on the weighted composite score we predicted changes in ε of six patients with a
third or fourth visit. The predicted values correlated strongly with the measured weighted com-
posite score (R2, 0.904; slope, 0.90 [0.70–1.11]; intercept, 0.14 [-0.55–0.83]; Fig 4A).
Fig 1. Visual acuity as a function of degrees of retinal eccentricity.
https://doi.org/10.1371/journal.pone.0174020.g001
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Accurate prediction of disease progression is validated in a replication
cohort
Using the identical weighted score in the mixed-effects model, we predicted the progression in
a separate replication cohort of 18 Stargardt patients, ascertained at Moorfields Eye Hospital in
Fig 2. Schematic and representative images of measurements in fundus autofluorescence imaging and spectral-domain optical coherence
tomography. Patient 9: area of questionably decreased autofluorescence (QDAF, blue), 1.37 mm2; area of definitely decreased autofluorescence (black),
0.33 mm2; transverse loss of external limiting membrane (ELM-loss, red), 1.75 mm, transverse loss of ellipsoid zone (EZ-loss, blue), 2.24 mm; best-
corrected visual acuity, 20/100; ABCA4 variants, c.1622T>C;3113C>T:p.[Leu541Pro;Ala1038Val] and c.6316C>T:p.(Arg2106Cys).
https://doi.org/10.1371/journal.pone.0174020.g002
Table 1. Yearly progression rate of changes in retinal eccentricity (ε) by visual function, fundus auto-
fluorescence and optical coherence tomography.
Slope (mean) Residual (SD) MSDR
Univariable outcomes
εBCVA 0.31˚/year 3.77˚/year 0.08
εQDAF 0.32˚/year 0.14˚/year 2.32
εDDAF 0.58˚/year 0.33˚/year 1.73
εELM 0.34˚/year 0.17˚/year 1.97
εEZ* 0.38˚/year * *
Composite outcomes
Unweighted (εBCVA, εQDAF, εDDAF, εELM, εEZ) 0.35˚/year 1.24˚/year 0.28
Unweighted (εQDAF, εDDAF, εELM, εEZ) 0.47˚/year 0.24˚/year 2.00
Optimal weight (15% εQDAF, 5% εDDAF, 15% εELM, 55% εEZ) 0.41˚/year 0.13˚/year 3.21
BCVA = best-corrected visual acuity, QDAF = questionably decreased autofluorescence, DDAF = definitely
decreased autofluorescence, ELM = external limiting membrane, EZ = ellipsoid zone, MSDR = mean-to
standard deviation ratio, SD = standard deviation, ε = retinal eccentricity.
*There were limited measurements available because it exceeded retinal scans.
https://doi.org/10.1371/journal.pone.0174020.t001
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London. One hundred and thirty-eight eye-visits were included (range, 2–6 visits per patient).
The London cohort was not significantly different to the Nijmegen cohort: with a median age at
disease onset of 8 years (range, 5–11; Mann-Whitney U, P = 0.419), and follow-up from 1.0 to
11.0 years (median, 4.5; Mann-Whitney U, P = 0.722). We observed an overall progression of
0.43˚/year (95% confidence interval, 0.33–0.53). Cohort characteristics compared to the Nijme-
gen cohort are further described in Table 2. Predicted values correlated with the measured
weighted composite score (R2, 0.872; slope, 1.17 [0.99–1.34]; intercept, -0.29 [-0.77–0.18]; Fig 4B).
Simulation reveals high statistical power despite small numbers of
patients and short follow-up
Finally, to assess the value of the composite biomarker in an interventional trial, we simulated a
randomized-controlled paired trial in 14 patients, with a two-year follow-up period, and differ-
ent treatment effects (Fig 5). Using the optimized weighted composite score as the primary end-
point, we obtained a statistical power of> 80% (with a significance level of 0.05) in the case of a
25% treatment effect. Unweighted structural scores decreased the power by approximately 50%.
Discussion
The genotypic and phenotypic heterogeneity of rare diseases are a challenge for designing ther-
apeutic clinical trials using conventional parameters. This affects many patients; current
Fig 3. Highest potential mean-to-standard deviation ratio (MSDR) for each single outcome measure at
different weightings with all possible weight combinations of the other metrics. MSDRs for best-
corrected visual acuity (grey) decrease at increasing weight. MSDRs for transition zones of questionably
decreased autofluorescence (blue) increase until 25% weight, but gradually decrease at higher weights.
MSDRs for transition zones of definitely decreased autofluorescence decrease at weights higher than 5%.
MSDRs for loss of the ellipsoid zone (green) are constant, but decrease substantially at weights higher than
approximately 70%. MSDRs for loss of the external limiting membrane (black) decrease at weights higher
than approximately 80%.
https://doi.org/10.1371/journal.pone.0174020.g003
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estimates are between 6.5 and 9.9 million inhabitants of the EU28 countries (1.3–2.0%).
Jointly, these diseases represent a relevant public health issue [32], and to evaluate novel treat-
ments, better strategies are needed. Current strategies use biomarkers, which are often in-
sufficient to provide appropriate sample size calculations, or require long-term follow-up (S1
Table). However, an integrated approach of these individual biomarkers can result in a reliable
and sensitive marker for disease progression. In this paper, we showed that such markers can
be developed using composite endpoints and weighting optimization techniques.
Fig 4. Weighted composite score and predicted outcome. Matching colors represent the right and left eye
of the same patient. (A) Results from six early-onset Stargardt patients. (B) The predicted outcome in the
replication cohort showed comparable results.
https://doi.org/10.1371/journal.pone.0174020.g004
Table 2. Characteristics of early-onset Stargardt cohorts from Radboud university medical center
(Radboudumc) and Moorfields Eye Hospital (MEH).
Radboudumc MEH
Patients 7 men 11 men
7 women 7 women
Baseline characteristics
Age at onset (years) 9 (4–11) 8 (5–11)
Age at baseline (years) 13 (9–26) 14 (8–25)
εBCVA (˚, Snellen equivalent) 12.76 (9.85–24.00), 20/200 12.62 (6.31–18.94), 20/200
εQDAF (˚, area equivalent) 4.22 (1.68–7.67), 5.03 mm2 4.64 (1.44–9.98), 6.10 mm2
εDDAF (˚, area equivalent) 1.80 (0–5.60), 0.92 mm2 2.40 (0–6.41), 1.63 mm2
εELM (˚, transverse equivalent) 5.09 (2.50–10.71), 3.05 mm 4.82 (2.06–7.71), 2.89 mm
εEZ (˚, transverse equivalent) 3.54 (2.99–7.83), 2.12 mm 5.87 (3.86–8.58), 3.52 mm
Disease progression
Follow-up (years) 4.73 (1.13–9.71) 4.47 (1.0–10.99)
Progression (˚/year) 0.41 (95% CI, 0.30–0.52) 0.43 (95% CI, 0.33–0.53)
Median and range are shown for baseline characteristics and follow-up. BCVA = best-corrected visual
acuity, CI = confidence interval, QDAF = questionably decreased autofluorescence, DDAF = definitely
decreased autofluorescence, ε = retinal eccentricity, ELM = external limiting membrane, EZ = ellipsoid zone,
SE = standard error, ε = retinal eccentricity.
https://doi.org/10.1371/journal.pone.0174020.t002
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The composite endpoint that we developed to sensitively measure disease progression in
patients with early-onset STGD1 was based on its spatiotemporal disease course. Although the
exact pathophysiological mechanisms of the disease pattern are still not completely understood,
natural history studies suggest a centrifugal expansion from macula-only to potentially retina-
wide disease [5, 15, 16, 29, 33]. Visual acuity failed to detect this gradual expansion due to its
low signal-to-noise ratio in the composite model. In the final model, the expansion of different
transition zones is analyzed by two widely available imaging techniques. SD-OCT can visualize
photoreceptor damage, represented by loss of the ellipsoid zone, followed by loss of the external
limiting membrane [34–36], and FAF imaging can detect RPE atrophy associated with photore-
ceptor dysfunction/loss [26]. In the future, the composite model may be further optimized by in-
corporating more sophisticated retinal imaging techniques such as adaptive optics scanning light
Fig 5. Power calculations of a simulated therapeutic trial based on fourteen early-onset Stargardt
patients. Dark blue line: a power of 80% is reached with a 25% overall treatment effect and a two-year follow-
up period. Purple line: the power will drastically decrease when best-corrected visual acuity is included in the
outcome measure. Turquoise line: worse eye treated. Green line: one-year follow-up. Ocher line: unweighted
structural composite. Red line: non-paired trial design. Yellow line: best-corrected visual acuity as a single
outcome measure.
https://doi.org/10.1371/journal.pone.0174020.g005
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ophthalmoscopy which affords in-vivo cellular imaging. Parameters derived from electrophysio-
logical assessment could also potentially strengthen the composite model, although it is limited by
significantly greater test-retest variability than aforementioned structural testing [37–39].
We are aware that, ultimately, the value of novel therapeutic modalities should be inferred
from their impact on outcomes that matter to patients. In the context of eye disease, these
would certainly include vision and the impact that visual impairments have on daily life
(patient-reported outcome measures). In addition, the long-term safety of such novel treat-
ments should be safeguarded. For these purposes, the metric that we have developed in this
study is unlikely to be appropriate in isolation, since its focus lies on structural abnormalities
alone. We believe its value mainly derives from the ability to rationally select promising novel
treatment modalities and also potentially facilitate patient selection for recruitment to clinical
trials. Consequently, it will need to be demonstrated that the employed structural parameters
correlate with functional outcome in the long term.
Multimodal analysis is a powerful technique, potentially reducing costs and duration of
clinical trials and also likely reducing beta errors in data analysis, thereby hopefully facilitating
effective treatments being identified more readily and rapidly for patients with rare diseases.
There is also the possibility of further improvements with the inclusion of other biomarkers in
the future, and the potential to be extrapolated to other disorders.
Materials and methods
Patient selection
We selected patients from the Stargardt databases of the Departments of Ophthalmology at Rad-
boud university medical center (Nijmegen, The Netherlands) and Moorfields Eye Hospital (Lon-
don, United Kingdom). We used the patient data from Radboud university medical center to
develop the progression model, and the data from Moorfields Eye Hospital to replicate the study.
We included patients with the faster progressive early-onset form of STGD1, harboring two or
more likely disease-causing sequence variants in ABCA4 (Table 3), and with at least one year fol-
low-up with FAF imaging and/or SD-OCT The early-onset phenotype typically presents with
foveal atrophy that may precede the development of yellow-white fundus flecks. Early-onset
STGD1 is associated with the most rapid deterioration of all patients with STGD1 [5]. We only
included patients with a reported disease onset<12 years of age [4, 5]. We excluded (1) patients
with very early disease in which only thickening of the external limiting membrane was present,
because this would preclude the OCT measurements, (2) patients with advanced disease charac-
terized by RPE atrophy beyond the vascular arcades at first presentation, and (3) patients who
participated in an interventional trial [40]. This study was approved by the local ethics committee
on Research Involving Human Subjects of the Radboud university medical center “Commissie
Mensgebonden Onderzoek Regio Arnhem-Nijmegen” and the National Research Ethics Service
(NRES) Committee London—Camden & Islington, and was performed in accordance with the
Declaration of Helsinki. All patients provided informed consent prior to receiving additional
ophthalmologic examinations. Written informed consent was obtained from parents, caretakers,
or guardians on behalf of the children below 18 years (at Radboud university medical center) or
below 16 years (at Moorfields Eye Hospital). Additional written informed consent was obtained
from children between 12 and 17 years old (at Radboud university medical center) or between 6
and 15 years old (not necessary, but preferable at Moorfields Eye Hospital).
Clinical examinations
We reviewed the records and imaging databases to extract information including BCVA, FAF
imaging, and SD-OCT. Best-corrected visual acuity was measured using a Snellen or Early
A multimodal model of progression in Stargardt disease
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Treatment Diabetic Retinopathy Study chart. Short-wave FAF imaging (λ = 488 nm, emission
500–700 nm) was performed using a confocal scanning laser ophthalmoscope (Spectralis HRA
+OCT or HRA2, Heidelberg Engineering, Heidelberg, Germany). The field of view was set at
30˚×30˚ or 55˚×55˚ and was centered at the macula. Cross-sectional images were obtained
using SD-OCT (Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany) cen-
tered at the macula (S1 Dataset).
Table 3. ABCA4 variants in early-onset Stargardt patients from Radboud university medical center (Radboudumc) and Moorfields Eye Hospital
(MEH).
Radboudumc
Patient Variant 1 Variant 2
1 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6]
2 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.214G>A p.(Gly72Arg)
3 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.5537T>C p.(Ile1846Thr)
4 c.768G>T p.(?) c.1822T>A p.(Phe608Ile)
5 c.3033-?_3364+?del p.(?) c.5714+5G>A p.(?)
6 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.5337C>A p.(Tyr1779*)
7 c.286A>G p.(Asn96Asp) c.286A>G p.(Asn96Asp)
8 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.4773+1G>A p.(?)
9 c.1622T>C;3113C>T p.[Leu541Pro;Ala1038Val] c.6316C>T p.(Arg2106Cys)
10 c.768G>T p.(?) c.768G>T p.(?)
11 c.3033-?_3364+?del p.(?) c.5714+5G>A p.(?)
12 c.4128+1G>A p.(?) c.3259G>A p.(Glu1087Lys)
13 c.4128+1G>A p.(?) c.3259G>A p.(Glu1087Lys)
14 c.4139C>T p.(Pro1380Leu) c.2160+1G>T p.(?)
MEH
Patient Variant 1 Variant 2
1 c.3191-1G>T p.(?) c.4139C>T p.(Pro1380Leu)
2 c.4462T>C p.(Cys1488Arg) c.4462T>C p.(Cys1488Arg)
3 c.6079C>T p.(Leu2027Phe) c.3322C>T p.(Arg1108Cys)
4 c.6479+1G>A p.(?) c.6479+1G>A p.(?)
5 c.6479+1G>A p.(?) c.6479+1G>A p.(?)
6 c.4469G>A p.(Cys1490Tyr) c.3197T>G p.(Met1066Arg)
7 c.4253+4C>T p.(?) c.4253+4C>T p.(?)
8 c.5461-10T>C p.[Thr1821Valfs*13,Thr1821Aspfs*6] c.3299T>A p.(Ile1100Asn)
9 c.768G>T p.(?) c.4139C>T p.(Pro1380Leu)
10 c.3081T>G p.(Tyr1027*) c.3081T>G p.(Tyr1027*)
11 c.6286G>A p.(Glu2096Lys) c.2894A>G p.(Asn965Ser)
12 c.4577C>T p.(Thr1526Met) c.3322C>T p.(Arg1108Cys)
13 c.93G>A p.(Trp31*) c.2522A>C p.(Gln841Pro)
14 c.4139C>T p.(Pro1380Leu) c.1957C>T p.(Arg653Cys)
15 c.6729+4_6729+18del p.(?) c.6729+4_6729+18del p.(?)
AGTTGGCCCTGGGGC AGTTGGCCCTGGGGC
16 c.5714+5G>A p.(?) c.1622T>C;3113C>T p.[Leu541Pro;Ala1038Val]
17 c.6729+4_6729+18del p.(?) c.6729+4_6729+18del p.(?)
AGTTGGCCCTGGGGC AGTTGGCCCTGGGGC
18 c.2912C>A p.(Thr971Asn) c.2912C>A p.(Thr971Asn)
del = deletion, fs = frame shift, ins = insertion
* = stop codon.
https://doi.org/10.1371/journal.pone.0174020.t003
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Functional measurements
We analyzed data with SAS Statistical Analysis Software Version 9.2 (SAS Institute, Cary, NC).
Best-corrected visual acuity can be expressed in retinal eccentricity (ε) to estimate the spatial
extent of retinal dysfunction spatially. It has been calculated previously that an object must
grow by 0.2˚ in size to maintain BCVA for each degree of eccentricity [30]. The BCVA is there-
fore reduced by a factor of 1/1.2 for each degree. This results in a transformed BCVA to the
estimated equivalent of ε:
BCVA ¼ ð
1
1:2
Þ
ε
ð1Þ
which can be written as
εBCVA ¼ log1=1:2 BCVA ð2Þ
Quantitative measurements on imaging
Abnormalities that were expected to consistently increase over time were included for quanti-
fication. Two independent authors (S.L. and N.M.B.), blinded to the each other’s findings,
manually delineated areas of abnormal autofluorescence signals based on darkness levels on
FAF imaging, and the loss of retinal layers on SD-OCT. These included areas of questionably
decreased autofluorescence (QDAF), definitely decreased autofluorescence (DDAF), trans-
verse loss of the external limiting membrane (ELM) and ellipsoid zone (EZ) on the OCT scan
through the fovea. All measurements were standardized to retinal eccentricity. One degree of
eccentricity corresponds to approximately 0.3 mm on the retina [41]. Therefore, the eccentric-
ity can be calculated as the radius of the circular equivalents of the sum of QDAF and DDAF
areas using the previously reported conversion factor:
εQDAF ¼ 0; 3
  1
ffiffiffiffiffiffiffiffiffiffiffiffiffi
QDAF
p
r
ð3Þ
and
εDDAF ¼ 0; 3
  1
ffiffiffiffiffiffiffiffiffiffiffiffiffi
DDAF
p
r
ð4Þ
As the transverse horizontal loss of retinal layers represents the diameter of a circular equiv-
alent, the eccentricities of ELM loss and EZ loss could be calculated as follows:
εEZ ¼ 0; 3
  1 EZ
2
ð5Þ
and
εELM ¼ 0; 3
  1 ELM
2
ð6Þ
Reproducibility of measurements
If the discrepancy between graders exceeded 1˚, the graders were asked to reach consensus on
the location and extent of the transition zone. To assess the intra-grader reproducibility, one
of the two graders (S.L.) measured each image by each method twice, with a two-month inter-
val between gradings of the same image. We calculated the absolute inter- and intrarater agree-
ment of εQDAF, εDDAF (5%), εELM, and εEZ by intraclass correlation coefficients with 95%
confidence intervals. Averaged values of the graders were used for final analyses.
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Modelling disease progression
The composite ΔC was constructed from changes in ε as measured in all univariable biomark-
ers:
DCijðDtikÞ ¼ ða ½εBCVAijðtikÞ   εBCVAijðti;0Þ þ b ½εQDAFijðtikÞ   εQDAFijðti;0Þ þ c ½εDDAFijðtikÞ
  εDDAF ijðti;0Þ þ d  ½εEZijðtikÞ   εEZijðti;0Þ þ e ½εELMijðtikÞ   εELMijðti;0ÞÞ=ðaþ bþ cþ d
þ eÞ ð7Þ
• a, b, c, d, and e are weighting scores for each biomarker.
The composite biomarker was used to detect disease progression in a linear two-level ran-
dom effects mixed model, which can describe expansion rates of a transition zone quite well
within a short period. It accounts for variations between patients and between the eyes of each
patient, and can thus incorporate a potential non-linear process in the variance components of
these random effect [42]:
DCijðDtikÞ ¼ ½sþ si þ sij  Dtik þ Eijk ð8Þ
• ΔCij(Δt) is the change of the composite score from baseline for the i
th patient in eye j at time
since baseline Δt,
• Δtik is the k
th follow-up time for patient i,
• s is the mean population slope (first level fixed effect),
• si are the deviations of the i
th patient’s slope from the population value (independent second
level random effects),
• sij are the deviations of the slope of both eyes in patient i from his mean regression line (inde-
pendent third level random effects),
• Eijk is the residual error.
The intercept of the model was set to zero, because differences from baseline were used.
Weighting scores optimization
Weighting scores were subsequently chosen by an optimization criterion [28], which was con-
structed by the ratio of the population mean slope and the residual standard deviation
(MSDR). The criterion was empirically evaluated for different combinations of weighting
scores of parameters:
MSDR ¼
s
RMSE
ð9Þ
• s is the mean population slope,
• RMSE (root-mean-square error) is the residual standard deviation, a scale-dependent mea-
sure for accuracy.
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The total number of unique combinations follows a binomial coefficient nþa  1n
  
, where n is
the number of intervals, and a is the number of biomarkers. Five biomarkers with 5% intervals
(20 steps from 0 to 100%) resulted in 24!
20!4!
¼ 10626 combinations, which could be tested within
reasonable computational time. A weighting of zero resulted in exclusion of that particular
biomarker. When a certain biomarker was missing or not measurable, the ΔC was calculated
by the changes in the other biomarkers with their respective weighting scores. The combina-
tion with the highest MSDR was eventually used in the final model (S2 Dataset and S1
Appendix).
Validation and replication of the model
In a subset of patients (six), in which three or more visits were available, we calculated disease
progression of the last visit. These final visits were excluded in the construction of the weighted
composite. We compared these scores with the predicted scores based on the mixed model.
Using identical weighting scores, we replicated the study in another cohort.
Trial simulations
Based on these calculations, the optimal composite score difference was used to perform simu-
lations of a two-year interventional trial with the change in retinal eccentricity as primary out-
come measured by the composite biomarker. By introducing a potential treatment effect, we
calculated the expected power of a trial with these patients. The treated eye was randomly
assigned by a Bernoulli distribution. The progression was then simulated as follows:
Difference of DCijðDtilþxÞ ¼ ½DCijðDtilþxÞ  adjusted RMSE   d   DCijðDtilÞ ð10Þ
where
d ¼ effect size ð0:1Þ  ½predicted DCijðDtilþxÞ   predicted DCitðDtilÞ ð11Þ
• difference of ΔCi,t(Δti,l+x) is the difference of the change of the composite score from baseline
for the ith patient in the jth eye t at x years after the last visit l, compared to the last visit.
• the adjusted RMSE was calculated for residual errors of follow-up measurements without
baseline measurements (Δti,0), where Eij is zero in all patients,
• the treatment effect δ was simulated from 0 to 1 by steps of 0.05 in treated eyes.
As the degree of abnormalities are highly correlated between left and right eyes [21, 23] the
power can be increased considerably when the fellow eye serves as the paired control. A
paired-samples T-test was therefore performed to assess the differences between eyes in pro-
gression of changes in retinal eccentricity. Power calculations were performed by 10000 simu-
lations for each data point (S2 Appendix).
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